How psychedelic drugs interact with serotonin receptors to potentially produce therapeutic benefits

5-MeO-DMT and related psychedelics may support antidepressant potential by targeting the serotonin receptor 5-HT1A, not just the commonly discussed 5-HT2A pathway. Researchers from Icahn School of Medicine at Mount Sinai synthesized and tested 5-MeO-DMT derivatives and used cell signaling assays and cryo-electron microscopy to identify compounds that preferentially activate 5-HT1A over 5-HT2A. A lead compound, 4-F, 5-MeO-PyrT, was found to be highly 5-HT1A selective. In a mouse model of depression, 4-F, 5-MeO-PyrT produced antidepressant-like effects that were effectively mediated by 5-HT1A. The findings suggest designing psychedelic-derived therapeutics that preserve therapeutic benefits while minimizing 5-HT2A-related hallucinogenic effects, and they highlight broader receptor complexity in psychedelic pharmacology.